Giuseppe Remuzzi, Director of the Mario Negri Institute for Pharmacological Research, to Serve on Tissera’s Scientific Advisory Board

TEL AVIV, Israel - April 20, 2004 - Tissera, Inc. (OTCBB:TSSR), a biotechnology company dedicated to the development and commercialization of tissue transplantation therapies utilizing novel tissue precursor regeneration technologies for the treatment of disease and organ transplantation, today announced the appointment of Professor Giuseppe Remuzzi, M.D. F.R.C.P., to the company’s Scientific Advisory Board . In addition, Barbara Imberti, will serve as Dr. Remuzzi’s assistant on the Scientific Advisory Board.

Dr. Remuzzi currently serves as the Director of the Mario Negri Institute for Pharmacological Research of the Negri Bergamo Laboratories, and Director of the Department of Nephrology and Dialysis at the Ospedali Riuniti of Bergamo Hospital in Bergamo, Italy. Prior to his current role, Dr. Remuzzi was appointed to Professor of Nephrology and Director of the Division of Immunology and Organ Transplantation at the same hospital.  Dr. Imberti works closely with Dr. Remuzzi at the Mario Negri Institute for Pharmacological Research in the Cell Biology and Xenotransplantation Laboratory in the field of stem cell tissue engineering.

Throughout his career, Dr. Remuzzi was instrumental in major advances in many areas of nephrology, with particular focus on platelet endothelial interactions, vascular prostaglandin biology, coagulation and renal disease, progression of renal disease, experimental models of glomerular damage, and transplant immunology and graft tolerance.

“Dr. Remuzzi can offer Tissera an incredible source of knowledge in kidney development and renal disease, “ said Vicki Rabenou, CEO of Tissera. “For the past 25 years, he has been on the cutting-edge of nephrology and has graciously accepted our offer to join our Scientific Advisory Board. We are very pleased to have assembled a world-class group of medical innovators to help guide Tissera in our search for organ transplantation and disease treatment alternatives.”

Dr. Remuzzi has authored more than 700 scientific articles, reviews and monographs and serves on editorial boards of numerous journals including the prestigious New England Journal of Medicine and is member of the International Advisory Board of The Lancet. In recognition of his achievements, he has been awarded in 1998 honorary memberships in the Association of American Physicians and the British Royal College of Physicians. In 2001 he was nominated Chairman of the Research Committee of the COMGAN (Commission on Global Advancement of Nephrology) of the International Society of Nephrology (ISN).

About Tissera

Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases in which organ transplantation is necessary, while minimizing the dosage of immunosuppressive drugs. Tissera licensed the worldwide exclusive rights to the technology developed at the renown Weizmann Institute of Science in Israel led by Professor Yair Reisner, who currently serves as the Chairman of Tissera’s Scientific Advisory Board. In this research, scientists successfully implanted embryonic human and porcine kidney precursor tissues in mice, which grew into functional kidneys. This research was published in Nature Medicine and attracted worldwide scientific and media attention. For more information, please visit: www.tissera.com.

Safe Harbor Statement

"Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing technology into a useful product, our moving forward with our plans for trials, and our plans to expand the Company's infrastructure. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to further finance our plans and unforeseen technical difficulties in developing our technology, which could among other things, delay or prevent product development and our planned results. For further risk factors see the Company's 10-KSB filed with the SEC for our latest fiscal year."